Boston Scientific (NYSE:BSX) delivered better-than-expected second-quarter results, fueled by strong organic growth and solid performances across major regions.
The company reported adjusted earnings per share of $0.75, beating the consensus estimate of $0.73. Revenue climbed to $5.06 billion, a 22.8% increase year-over-year, outperforming the forecasted $4.89 billion. On an organic basis, sales grew 17.4% compared to the prior year.
“This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth,” said Mike Mahoney, chairman and CEO of Boston Scientific.
The U.S. market experienced robust growth of 30.7%, while Asia-Pacific sales rose 18%. The EMEA and Latin American regions posted more moderate increases, and emerging markets contributed positively with healthy gains.
For the third quarter, Boston Scientific expects adjusted EPS between $0.70 and $0.72, in line with analyst estimates of $0.70.
Looking ahead, the company projects full-year 2025 earnings per share in the range of $2.95 to $2.99, above the consensus estimate of $2.92.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.